[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353366-105":59,"doc-detail-353366-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","interpreting-homologous-recombination-deficiency-in-rare-gynecological-cancers-a-case-of-primary-mucinous-endometrial-adenocarcinoma-of-gastrointestinal-type","Interpreting homologous recombination deficiency in rare gynecological cancers - A case of primary mucinous endometrial adenocarcinoma of gastrointestinal type","","Mucinous endometrial carcinoma of gastric type (MCG) is rare and aggressive, with no established standard of care. Homologous recombination deficiency (HRD) biomarkers, including BRCA1/2 alterations and genomic signatures, are used to predict platinum and PARP inhibitor (PARPi) sensitivity, yet their value in rare gynecologic cancers remains uncertain. A 52-year-old patient with metastatic TP53-abnormal MCG showed germline BRCA1 mutation and high HRDetect score, but rapid progression after platinum and niraparib, supported by non-HRD copy-number signatures and PARP-inhibition resistance in a PDX model.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/interpreting-homologous-recombination-deficiency-in-rare-gynecological-cancers-a-case-of-primary-mucinous-endometrial-adenocarcinoma-of-gastrointestinal-type/353366/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/interpreting-homologous-recombination-deficiency-in-rare-gynecological-cancers-a-case-of-primary-mucinous-endometrial-adenocarcinoma-of-gastrointestinal-type/353366.png","ImageObject",300,407,{"name":92,"@type":93},"OmBimo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"为什么HRD生物标志物在罕见妇科癌症中的作用仍存在不确定性？","Question",{"text":112,"@type":113},"文章指出，尽管HRD相关指标被用于预测铂类化疗和PARP抑制剂（PARPi）的敏感性，但在罕见妇科癌症中的实用价值仍不明确。","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"该病例中发现了哪些与HRD相关的基因与分析结果？",{"text":117,"@type":113},"全基因组与转录组分析显示存在致病性的BRCA1生殖系突变，并伴随体细胞杂合缺失（LOH），导致双等位BRCA1丢失；同时HRDetect评分较高（0.96）支持HRD表型。",{"name":119,"@type":110,"acceptedAnswer":120},"尽管具有HRD证据，患者对PARPi为什么仍出现快速进展？",{"text":121,"@type":113},"患者在完成铂类治疗并开始维持性尼拉帕尼后，疾病在三个月内迅速进展。回顾性拷贝数分析将肿瘤归类为非HRD签名（高倍性为特征），且PDX模型显示对顺铂有反应，但对PARP抑制存在内在耐药。","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353366,1790444495,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962090893581,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Gynecologic Oncology Reports 66 (2026) 102180  \nContents lists available at ScienceDirect  \nGynecologic Oncology Reports  \njournal [homepage:](homepage: www.elsevier.com/locate/gynor)[ www.elsevier.com/locate/gynor](homepage: www.elsevier.com/locate/gynor)  \nInterpreting homologous recombination deficiency in rare gynecological cancers: A case of primary mucinous endometrial adenocarcinoma of gastrointestinal type  \nFarhia Kabeera,b, Dawn Cochrane b,c, Cam Grisdaled, Branden J. Lynch a,b,  \nMelissa K. McConechyd, Juliana Sobral de Barrosa,b, Lindsay Zibrik d, Janine Senza,b, Amy Jamieson c, Jessica N. McAlpine c, Blake Gilksb, Marco A. Marrae, Janessa Laskinf,g, Yvette Drew f,g,*  \na Department of Basic and Translational Research, BC Cancer Research Institute, Vancouver, BC, Canada  \nb Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada  \nc Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada d Canada's Michael Smith Genome Sciences Centre, Vancouver, BC, Canada  \ne Department of Medical Genetics and the Michael Smith Laboratories, University of British Columbia and BC Cancer Research Institute, Vancouver, BC, Canada f Department of Medical Oncology, BC Cancer Centre, Vancouver, BC, Canada  \ng Division of Medical Oncology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada  \nA R T I C L E I N F O  \nKeywords:  \nMucinous endometrial carcinoma of gastric type (MCG)  \nBRCA1 mutation  \nHomologous recombination deficiency PARPi resistance  \nPrecision oncology  \nA B S T R A C T  \nBackground: Mucinous endometrial carcinoma of gastric type (MCG) is a rare and aggressive malignancy with no established standard of care. Biomarkers of homologous recombination deficiency (HRD), including BRCA1/2 alterations and genomic signatures, are increasingly used to predict sensitivity to platinum-based chemotherapy and poly(ADP-ribose) polymerase inhibitors (PARPi), but their utility in rare gynecologic cancers remains unclear.  \nCase presentation: We report a 52-year-old female with metastatic TP53-abnormal endometrial MCG. Wholegenome and transcriptome analysis identified a pathogenic germline BRCA1 mutation with somatic loss of heterozygosity (LOH), resulting in biallelic BRCA1 loss. A high HRDetect score (0.96) further supported an HRD phenotype. The patient achieved an initial partial response to frontline platinum-based chemotherapy. However, despite genomic evidence predicting PARPi sensitivity, she experienced rapid disease progression within three months of completion of platinum and starting maintenance niraparib. Retrospective copy-number signature analysis classified the tumor as a non-HRD signature characterized by high ploidy rather than classic BRCAassociated genomic scarring. To further investigate treatment response, a patient-derived xenograft (PDX) model was established. The model faithfully recapitulated the clinical phenotype, showing response to cisplatin but intrinsic resistance to the PARP inhibition.  \nConclusion: This case demonstrates a discordance between genomic HRD biomarkers and therapeutic response. Despite germline BRCA1 mutation, somatic LOH, and a high HRDetect score, platinum response was not durable and PARPi sensitivity was not observed. These findings highlight the limitations of current HRD biomarkers in rare gynecologic cancers and support integrating functional and genomic approaches to guide precision oncology.  \n1. Introduction  \nDeficiencies in the homologous recombination DNA repair (HRR) pathway result in accumulation of unrepaired DNA double-strand  \nbreaks and genomic instability (Li et al., 2025). Homologous recombination deficiency (HRD) is a characteristic of several cancers, most notably high-grade serous ovarian cancer, where ~50% are HRD. The most common cause of HRD is biallelic inactivation of BRCA or other  \n* Correspon","cbCaifvIoD3VrdaP","https://ap.wps.com/l/cbCaifvIoD3VrdaP","pdf",2862266,"English","# A R T I C L E I N F O\n## Keywords\n## Abstract\n# 1. Introduction","[{\"question\":\"为什么HRD生物标志物在罕见妇科癌症中的作用仍存在不确定性？\",\"answer\":\"文章指出，尽管HRD相关指标被用于预测铂类化疗和PARP抑制剂（PARPi）的敏感性，但在罕见妇科癌症中的实用价值仍不明确。\"},{\"question\":\"该病例中发现了哪些与HRD相关的基因与分析结果？\",\"answer\":\"全基因组与转录组分析显示存在致病性的BRCA1生殖系突变，并伴随体细胞杂合缺失（LOH），导致双等位BRCA1丢失；同时HRDetect评分较高（0.96）支持HRD表型。\"},{\"question\":\"尽管具有HRD证据，患者对PARPi为什么仍出现快速进展？\",\"answer\":\"患者在完成铂类治疗并开始维持性尼拉帕尼后，疾病在三个月内迅速进展。回顾性拷贝数分析将肿瘤归类为非HRD签名（高倍性为特征），且PDX模型显示对顺铂有反应，但对PARP抑制存在内在耐药。\"}]","Interpreting homologous recombination deficiency in rare gynecological cancers - A case of primary mucinous endometrial adenocarcinoma of gastrointestinal type | PDF",1790104914,15,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8e0c4e480f4555821a8449df429bdc9.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2744f90a4d621b9e7670e6cd916d2df.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d8ce194f7eadd5bebc1747759576f0ee.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78f45ddbaee31d37be04281dc78010d4.webp",980,1306]